Pacer Advisors Inc. Has $594.37 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Pacer Advisors Inc. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 723.3% in the fourth quarter, HoldingsChannel reports. The firm owned 6,434,665 shares of the biopharmaceutical company’s stock after buying an additional 5,653,075 shares during the period. Gilead Sciences makes up approximately 1.3% of Pacer Advisors Inc.’s investment portfolio, making the stock its largest position. Pacer Advisors Inc.’s holdings in Gilead Sciences were worth $594,370,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in GILD. nVerses Capital LLC purchased a new position in Gilead Sciences in the 3rd quarter worth $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $29,000. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences in the second quarter valued at approximately $33,000. Finally, Friedenthal Financial acquired a new position in Gilead Sciences in the 3rd quarter worth approximately $50,000. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $93.07 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a 50-day moving average price of $91.74 and a 200 day moving average price of $85.09. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The stock has a market cap of $115.99 billion, a P/E ratio of 1,034.11, a PEG ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.29 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on GILD shares. BMO Capital Markets boosted their price objective on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Oppenheimer increased their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Robert W. Baird boosted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Finally, Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.